BPC-157: Evidence Simplified

An authoritative, citation-backed reference on BPC-157 (Body Protection Compound), the fifteen-amino-acid pentadecapeptide at the frontier of regenerative research. Few molecules in modern regenerative medicine have generated as much enthusiasm — and as much skepticism — as BPC-157. After more than thirty years of preclinical work, the molecule has acquired a following among athletes, biohackers, and patients with chronic musculoskeletal injuries, while remaining unapproved by the FDA, EMA, and every other major regulator, and prohibited at all times for athletes under the WADA Prohibited List. Eleven chapters move from the molecule to the patient and beyond: origins and chemistry; proposed mechanisms of action; the preclinical evidence for musculoskeletal, gut, and wound healing; neurological and systemic effects; the limited human evidence and global regulatory status; formulations (topical, oral, intranasal, sublingual); dosing protocols; a head-to-head comparison with TB-500; a continent-by-continent regulatory map; clinical applications organized by indication; and veterinary use in companion animals. Every nontrivial claim is tagged with an evidence-level label (HUMAN RCT, HUMAN OBS, ANIMAL, IN VITRO, HYPOTHESIS) and an inline citation to the primary literature. By Fady Hannah-Shmouni, MD FRCPC — Clinical Endocrinologist & Geneticist, Founder & CEO of Hormonaly.ai.